Cardiology 2013

Notes: Corrao, Simona

La Rocca, Giampiero

Lo Iacono, Melania

Zummo, Giovanni

Gerbino, Aldo

Farina, Felicia

Anzalone, Rita

eng

Research Support, Non-U.S. Gov’t

Review

United Arab Emirates

2013/01/03 06:00

Curr Stem Cell Res Ther. 2013 Jan;8(1):39-45.

URL: http://www.ncbi.nlm.nih.gov/pubmed/23278911

Author Address: Istituto Euro-Mediterraneo di Scienza e Tecnologia (IEMEST), Palermo, Italy.

 

 

Reference Type:  Journal Article

Record Number: 547Author: Cortese, B., Berti, S., Biondi-Zoccai, G., Colombo, A., Limbruno, U., Bedogni, F., Cremonesi, A., Silva, P. L. and Sgueglia, G. A.

Year: 2014

Title: Drug-coated balloon treatment of coronary artery disease: A position paper of the Italian Society of Interventional Cardiology

Journal: Catheter Cardiovasc Interv

Volume: 83

Issue: 3

Pages: 427-35

Date: Feb 15

Short Title: Drug-coated balloon treatment of coronary artery disease: A position paper of the Italian Society of Interventional Cardiology

Alternate Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

ISSN: 1522-726X (Electronic)

1522-1946 (Linking)

DOI: 10.1002/ccd.25149

Accession Number: 23934956

Abstract: Drug-coated balloons are a new tool for the treatment of patients with coronary artery disease. The main feature of this technology is a rapid and homogenous transfer of an antiproliferative drug (paclitaxel) to the vessel wall just at the time of balloon inflation, when neointimal proliferation, in response to angioplasty, is the highest. Moreover, drug-coated balloons share adjuntive advantages over stents: the absence of permanent scaffold and polymer, the respect of the original coronary anatomy, and limited inflammatory stimuli, thereby allowing for short-term dual antiplatelet therapy. To this day, a lot of devices are available in the market, with limited scientific data for the vast majority of them. Thus, the Italian scientific society of interventional cardiologists GISE decided to coordinate the efforts of a group of reknown experts on the field, in order to obtain a Position Paper on the correct use of drug-coated balloons in all the settings of coronary artery disease, giving a class of indication to each one, based on the clinical evidence. This Position Paper represents a quick reference for operators, investigators, and manufactures to promote the understanding and the correct use of the drug-coated balloon technology in everyday clinical practice. (c) 2013 Wiley Periodicals, Inc.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208